Does Ibogaine
Actually Work?

How We Measure Ibogaine Treatment Success

At MindScape Retreat, success is not defined by how a patient feels the morning after treatment. It is defined by validated clinical instruments, structured follow-up at 1 month, 3 months, and 6 months, and patient-reported outcomes measured against standardized baselines. For PTSD, we use the PCL-5 (PTSD Checklist for DSM-5), the same scale used in the landmark Stanford University ibogaine study published in Nature Medicine. For opioid and addiction cases, we track withdrawal symptom severity, craving intensity, and relapse rates at defined intervals.

Most treatment centers report success based on testimonials and patient satisfaction at discharge. We believe that is insufficient. Testimonials are meaningful, but they are not data. Our outcomes tracking methodology borrows from clinical trial design: every patient receives a baseline assessment before treatment, and follow-up assessments are conducted at standardized intervals after. The difference in scores is our measure. This is what allows us to state, with clinical confidence, that 98.6% of our PTSD patients achieved PCL-5 scores below the clinical threshold at six months.

We also track negative outcomes. Not every patient responds equally, and we report this honestly. A small percentage of patients across all conditions report incomplete or minimal response. Understanding why some patients respond differently from others is an ongoing priority for our clinical team. Factors we have identified include metabolizer phenotype, prior medication burden, and engagement with post-treatment integration therapy. Transparency about both success and limitation is, in our view, the foundation of evidence-based medicine.

Success Rates Across Treatment Categories

The Neurological Basis for These Outcomes

Ibogaine's therapeutic effects arise from a multi-receptor pharmacological profile that has no close parallel among approved psychiatric medications. At the core of its efficacy is the upregulation of GDNF (glial cell line-derived neurotrophic factor), a protein essential to the survival and function of dopaminergic neurons. GDNF promotes neuroregeneration, reduces neuroinflammation, and supports the structural repair of neural circuits damaged by addiction, trauma, and chronic stress. No approved antidepressant or addiction medication has been demonstrated to produce GDNF upregulation at therapeutic doses.

Noribogaine, ibogaine's primary active metabolite, extends these benefits for months after a single treatment. It binds with high affinity to the serotonin transporter, inhibiting serotonin reuptake and producing a sustained antidepressant effect that does not depend on continued dosing. It also activates the sigma-2 receptor, which is associated with neuroprotective and anti-apoptotic signaling in neural tissue, making it particularly relevant for TBI and neuroinflammatory conditions. Its modulation of the kappa-opioid receptor reduces stress reactivity and anxious arousal without the dependence potential of classical opioids.

The result of this multi-receptor engagement is a neuroplastic window: a period of heightened neural flexibility following treatment during which the brain is unusually receptive to new learning, emotional reprocessing, and behavioral change. This is why integration therapy in the weeks and months after ibogaine treatment is so consequential. The medicine opens the architecture; integration determines what is built within it. Our 90-day post-retreat program is designed to work with this window systematically.

What the Science Says About Ibogaine

A landmark 2023 study from Stanford University School of Medicine, published in Nature Medicine, examined ibogaine's effects on military veterans with traumatic brain injury and PTSD. The study reported significant reductions in PTSD symptom severity, depression, and anxiety, alongside improvements in cognitive function, following a single ibogaine treatment session in a medically supervised setting in Mexico. The magnitude of improvement was among the largest reported in any psychedelic or psychiatric intervention studied to date, prompting calls for expanded clinical trials.

The Multidisciplinary Association for Psychedelic Studies (MAPS) and researchers at institutions including Johns Hopkins, NYU, and the University of British Columbia have published observational and mechanistic data supporting ibogaine's anti-addictive and neuroprotective properties. Studies on GDNF upregulation establish the cellular mechanism underlying addiction interruption. Research on noribogaine's receptor binding profile explains the sustained antidepressant and anti-anxiety effects observed in longitudinal patient cohorts. The evidence base, while still developing by the standards of large-scale randomized controlled trials, is substantive and growing.

MindScape Retreat contributes to this evidence base through our own outcomes data. We have treated over 900 patients across addiction, PTSD, depression, neurological conditions, and SSRI discontinuation since 2019, with standardized intake assessment and follow-up at 1, 3, and 6 months. We share de-identified aggregate outcomes data with researchers studying ibogaine's clinical applications. Science advances when practitioners and researchers work together, and we are committed to that collaboration.

Outcome Questions